Search results for "Arthritis"

showing 10 items of 1029 documents

Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009.

2017

Objective.To describe deaths for which ankylosing spondylitis (AS) was on death certificates in France.Methods.Death certificates in which AS was indicated were evaluated. Standard mortality ratio (SMR) was assessed.Results.AS appeared in 2940 death certificates. The mortality rate of AS seemed stable. The most frequent initial causes were diseases of the circulatory system [28.3% in the International Classification of Diseases, 10th ed (ICD-10)]. SMR adjusted for age and sex were 2.1 (95% CI 1.45–2.91) for infections and 0.43 (0.36–0.5) for cancers (ICD-10 period).Conclusion.This study found an increase in mortality from infectious and external causes of death; conversely, patients with AS…

AdultMalemedicine.medical_specialtyImmunologyAge and sexDeath Certificates03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineCause of DeathmedicineImmunology and AllergyHumansSpondylitis Ankylosing030212 general & internal medicineAged030203 arthritis & rheumatologyAged 80 and overAnkylosing spondylitisbusiness.industryMortality rateCancerMiddle Agedmedicine.diseaseSurgeryStandardized mortality ratioFemaleDeath certificateFrancebusinessThe Journal of rheumatology
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

The in vitro addition of methotrexate and/or methylprednisolone determines peripheral reduction in Th17 and expansion of conventional Treg and of IL-…

2014

The aim of our study was to evaluate methotrexate (MTX) and methylprednisolone (MP) effect on peripheral Th17 and Treg subsets in patients with rheumatoid arthritis (RA). We enrolled 15 patients (10 early RA and 5 long-standing disease) with active RA and 10 age-matched healthy donors as controls. Frequencies of Th17 and Treg were quantified using flow cytometry before and after in vitro addition of MTX, MP or both drugs. Our results showed a reduction in the overall Th17 population followed by an increase in Th17 IL-10+ and Treg, after in vitro treatment of PBMCs with the drugs in patients with early RA. Long-standing disease patients showed a less evident increase in Treg cells and less e…

AdultMalemedicine.medical_specialtyImmunologyPopulationArthritischemical and pharmacologic phenomenaPeripheral blood mononuclear cellMethylprednisoloneT-Lymphocytes RegulatoryArthritis RheumatoidRheumatologyInternal medicinemedicineImmunology and AllergyHumanseducationRheumatoid arthritieducation.field_of_studybusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseRheumatologyInterleukin-10TregSettore MED/16 - ReumatologiaMethotrexateMethylprednisoloneRheumatoid arthritis Th17 TregRheumatoid arthritisAntirheumatic AgentsImmunologyTh17 CellsMethotrexateFemaleTh17Interleukin 17businessmedicine.drug
researchProduct

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open st…

1992

In vitro studies on the effects of dexamethasone on human synovial cells have shown that with high concentrations of the steroid in the culture medium cellular activity was completely blocked whereas with low concentrations (10(-6)M), cellular density decreased but there was an increase in the synthesis of RNA, DNA, protein and hyaluronic acid. These data, coupled with clinical experience of using intra-articular hyaluronic acid to treat patients with osteoarthritis of the knee, prompted the investigators to carry out an open, randomized study of the use of very small doses of dexamethasone in association with hyaluronic acid in 40 osteoarthritic patients. Twenty patients received a weekly …

AdultMalemedicine.medical_specialtyKnee Jointmedicine.drug_classmedicine.medical_treatmentSodium hyaluronatePainOsteoarthritismedicine.disease_causeDexamethasoneDrug Administration ScheduleInjections Intra-ArticularWeight-bearinglaw.inventionchemistry.chemical_compoundRandomized controlled triallawOsteoarthritisHyaluronic acidmedicineHumansHyaluronic AcidDexamethasoneAgedPain MeasurementChemotherapybusiness.industryDrug SynergismGeneral MedicineMiddle Agedmedicine.diseaseSurgeryMolecular WeightchemistryAnesthesiaCorticosteroidFemalebusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis.

1995

Islet cell antigen (ICA) 69 is a newly-recognized islet cell antigen to which autoantibodies have been observed in prediabetic relatives of patients with insulin-dependent-diabetes mellitus (IDDM). Here we extend the earlier analysis of ICA69 antibodies to patients with recent-onset IDDM and to patients with other immune-mediated diseases. ICA69 antibodies were determined by Western blot using an affinity purified recombinant fusion protein of ICA69 and maltose binding protein. ICA69 antibody quantities were determined as titres using a titration curve of a standard serum as reference. Mean logarithmic ICA69 antibody titres were 3.4 (+/- 1.4) in 99 patients with acute IDDM compared to 2.8 (…

AdultMalemedicine.medical_specialtyMultiple SclerosisTime Factorsendocrine system diseasesAdolescentEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsBlotting WesternArthritisAutoantigensArthritis RheumatoidAntigenCrohn DiseaseInternal medicineImmunopathologyInternal MedicinemedicineHumansFamilyChildAutoantibodiesAutoimmune diseasegeographygeography.geographical_feature_categorybiologybusiness.industryAutoantibodyThyroiditis AutoimmuneInfantMiddle AgedIsletmedicine.diseaseGraves DiseaseEndocrinologyDiabetes Mellitus Type 1Rheumatoid arthritisChild PreschoolImmunologybiology.proteinColitis UlcerativeFemaleAntibodybusinessFollow-Up StudiesDiabetologia
researchProduct

Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era.

2019

Author's accepted manuscript. This is a pre-copyediting, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version Berg, K. H., Rohde, G., Prøven, A., Benestad, E. E. P., Østensen, M. & Haugeberg, G. (2019). Sexual Quality of Life in Patients with Axial Spondyloarthritis in the Biologic Treatment Era. The Journal of Rheumatology, 46(9), 1075-1083 is available online at: https://www.jrheum.org/content/46/9/1075. Objective. To examine the relationship between demographics, disease-related variables, treatment, and sexual quality of life (SQOL) in men and women with axial spondyloarthritis (ax…

AdultMalemedicine.medical_specialtyMultivariate analysisSexual BehaviorImmunologyDiseasePersonal SatisfactionSeverity of Illness IndexBody Mass Index03 medical and health sciences0302 clinical medicineSex FactorsRheumatologyQuality of lifeInternal medicineSurveys and QuestionnairesSpondylarthritisImmunology and AllergyMedicineOutpatient clinicHumans030212 general & internal medicineAxial spondyloarthritisBASDAI030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle AgedRheumatologyVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Reumatologi: 759Antirheumatic AgentsQuality of LifeFemalebusinessBASFIThe Journal of rheumatology
researchProduct

Risk for periodontal disease in patients with longstanding rheumatoid arthritis.

1998

Objective. To quantify periodontal disease in rheumatoid arthritis (RA) patients and controls, and to correlate the degree of destruction from periodontal disease and from RA Methods. Fifty RA patients were matched for age, sex, smoking status, and oral hygiene with 101 controls. Correlations between indices of chronic destruction in periodontal disease (gingival attachment loss) and in RA (Larsen radiographic score) were determined. Results. Patients with longstanding active RA (mean ± SD 13 ± 8 years) who were receiving treatment with disease-modifying antirheumatic drugs (n = 46), corticosteroids (n = 38), or nonsteroidal antiinflammatory drugs (n = 43) had a higher rate of gingival blee…

AdultMalemedicine.medical_specialtyOral Hygiene IndexImmunologyGingivaArthritisDentistryOral hygieneGastroenterologyArthritis RheumatoidRheumatologyRisk FactorsInternal medicineImmunopathologyOral and maxillofacial pathologymedicineImmunology and AllergyHumansPharmacology (medical)Risk factorArthrographyAgedAutoimmune diseasebusiness.industryMiddle Agedmedicine.diseaseOral HygieneClinical attachment lossRheumatoid arthritisGingival DiseasesDisease ProgressionFemaleJointsbusinessArthritis and rheumatism
researchProduct

Bone Mineral Density and Vitamin D Status in Female and Male Patients with Osteoarthritis of the Knee or Hip

2008

&lt;i&gt;Objective:&lt;/i&gt; Osteoporosis (OP), osteoarthritis (OA) and vitamin D deficiency are age-related disorders. We investigated the association between bone mineral density (BMD), vitamin D and OA in patients undergoing total hip or knee replacements. &lt;i&gt;Method:&lt;/i&gt; In total, 82 women and 35 men with mean ages of 70 and 68 years, respectively, were recruited for the study. The BMD of the lumbar spine and the proximal femur were measured by dual-energy X-ray absorptiometry. The vitamin D status was assessed by 25(OH)D levels, with a cut-off of ≤30 ng·ml&lt;sup&gt;–1&lt;/sup&gt;. &lt;i&gt;Results:&lt;/i&gt; In total, 84.7% of the patients had a vitamin D deficiency; 20% o…

AdultMalemedicine.medical_specialtyOsteoporosisOsteoarthritisOsteoarthritis Hipvitamin D deficiencyBody Mass IndexAbsorptiometry PhotonBone DensityInternal medicinemedicineVitamin D and neurologyHumansVitamin DAgedAged 80 and overBone mineralSex Characteristicsbusiness.industryAge FactorsMiddle AgedOsteoarthritis KneeVitamin D Deficiencymedicine.diseaseBone Diseases MetabolicEndocrinologyMale patientOsteoporosisFemaleSurgerybusinessEuropean Surgical Research
researchProduct